Association between the N-terminally truncated (ΔN) p63α (ΔNp63α) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 115, Issue 3, 2009, Pages 424-429

  Jewell, Elizabeth L ^a   Darcy, Kathleen M ^b   Hutson, Alan ^b   Lee, Paula S ^a   Havrilesky, Laura J ^a   Grace, Lisa A ^a   Berchuck, Andrew ^a   Secord, Angeles Alvarez ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Np63 ; Angiogenic markers; Ovarian carcinoma; p53; Prognosis; VEGF

Indexed keywords

BETA ACTIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; FIBROBLAST GROWTH FACTOR; MASPIN; PACLITAXEL; PROTEIN P53; PROTEIN P63; PROTEIN P63 ALPHA; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; EPITHELIAL OVARY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTEIN ISOFORMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350569893     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.07.035     Document Type: Article

References (33)

1. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dötsch V., et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2 (1998) 305-316
2. Moll U.M., and Slade N. p63 and p73: roles in development and tumor formation. Mol. Cancer Res. 2 (2004) 371-386
3. Yang A., Kaghad M., Caput D., and McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 18 (2002) 90-95 Review
4. Westfall M.D., and Pietenpol J.A. p63: Molecular complexity in development and cancer. Carcinogenesis 25 (2004) 857-864
5. Wu G., Nomoto S., Hoque M.O., Dracheva T., Osada M., Lee C.C., et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 63 (2003) 2351-2357
6. Sniezek J.C., Matheny K.E., Westfall M.D., and Pietenpol J.A. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 114 (2004) 2063-2072
7. Wu M., Wang B., Gil J., Sabo E., Miller L., Gan L., et al. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am. J. Clin. Pathol. 119 (2003) 696-702
8. Ribeiro-Silva A., Becker de Moura H., Ribeiro do Vale F., and Zucoloto S. The differential regulation of human telomerase reverse transcriptase and vascular endothelial growth factor may contribute to the clinically more aggressive behavior of p63-positive breast carcinomas. Int. J. Biol. Markers 20 (2005) 227-234
9. Di Como C.J., Urist M.J., Babayan I., Drobnjak M., Hedvat C.V., Teruya-Feldstein J., et al. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 8 (2002) 494-501
10. Reis-Filho J.S., Simpson P.T., Martins A., Preto A., Gärtner F., and Schmitt F.C. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 443 (2003) 122-132
11. Poli Neto O.B., Candido Dos Reis F.J., Zambelli Ramalho L.N., Nogueira A.A., and de Andrade J.M. p63 expression in epithelial ovarian tumors. Int. J. Gynecol. Cancer 16 (2006) 152-155
12. Wang Y., Kringen P., Kristensen G.B., Holm R., Baekelandt M.M., Olivier M., et al. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum. Mutat. 24 (2004) 21-34
13. Shao S.L., Cai Y., Wang Q.H., Yan L.J., Zhao X.Y., and Wang L.X. Expression of GLUT-1, p63 and DNA-PKcs in serous ovarian tumors and their significance. Zhonghua Zhong Liu Za Zhi 29 (2007) 697-700
14. Marchini S., Marabese M., Marrazzo E., Mariani P., Cattaneo D., Fossati R., et al. DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann. Oncol. 19 (2008) 501-507
15. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the GOG, SWOG, and ECOG. J. Clin. Oncol. 19 (2001) 1001-1007
16. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J. Clin. Oncol. 18 (2000) 106-115
17. Havrilesky L.J., Alvarez A.A., Whitaker R.S., Marks J.R., and Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol. Oncol. 83 (2001) 491-500
18. Havrilesky L., Darcy K.M., Hamdan H., Priore R.L., Leon J., Bell J., et al. Relationship between p53 mutation, p53 overexpression and survival in advanced ovarian cancer: A Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3814-3825
19. Secord A.A., Lee P.S., Darcy K.M., Havrilesky L.J., Grace L., Marks J., et al. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study. Gynecol. Oncol. 101 (2006) 390-397
20. Secord A.A., Darcy K.M., Hutson A., Lee P.S., Havrilesky L.J., Grace L.A., et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol. Oncol. 106 (2007) 221-232
21. Kruskal W.H., and Wallis W.A. Use of ranks in one-criterion variance analysis. J. Am. Stat. Assoc. 47 (1952) 583-621
22. Spearman C. The proof and measurement of association between two things. Amer. J. Psychol. 15 (1904) 71-101
23. Cox D.R. Regression models and life tables. J. Royal. Stat. Soc. 34 (1972) 187-220
24. Hosmer DW, Lemeshow S: Applied survival analysis-regression modeling of time to event Data. New York, John Wiley and Sons, Inc., 1999, pp 93-105, pp 158-195, pp 205-216.
25. Liao X.Y., Xue W.C., Shen D.H., Ngan H.Y., Siu M.K., and Cheung A.N. p63 expression in ovarian tumours: A marker for Brenner tumours but not transitional cell carcinomas. Histopathology 51 (2007) 477-483
26. Miller K., Price J.H., Dobbs S.P., McClelland R.H., Kennedy K., and McCluggage W.C. An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma. J. Clin. Pathol. 61 (2008) 652-657
27. Zangen R., Ratovitski E., and Sidransky D. DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle 4 (2005) 1313-1315
28. Deyoung M.P., Johannessen C.M., Leong C.O., Faquin W., Rocco J.W., and Ellisen L.W. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res. 66 (2006) 9362-9368
29. Muller M., Schleithoff E.S., Stremmel W., Melino G., Krammer P.H., and Schilling T. One, two, three-p53, p63, p73 and chemosensitivity. Drug Resist. Update 9 (2006) 288-306
30. Ratovitski E., Trink B., and Sidransky D. p63 and p73: Teammates or adversaries?. Cancer Cell 9 (2006) 1-2
31. Rocco J.W., Leong C.O., Kuperwasser N., DeYoung M.P., and Ellisen L.W. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9 (2006) 45-56
32. Deyoung M.P., and Ellisen L.W. . p63 and p73 in human cancer: Defining the network. Oncogene 26 (2007) 5169-5183
33. Senoo M., Matsumura Y., and Habu S. TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. Oncogene 21 (2002) 2455-2465